A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

Lilly

Status and phase: Completed; Phase 1

Conditions: Diabetes Mellitus, Type 1

Treatments: Drug: Placebo; Drug: LY3532226

Study type: Interventional

Funder types: Industry

Identifiers

NCT05887999

J2V-MC-GZLC (Other Identifier)

18064

Details and patient eligibility

About

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

Enrollment: 30 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
• Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
• Are males or females not of childbearing potential

Exclusion criteria

• Have acute proliferative retinopathy requiring active treatment within 3 months of screening
• Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
• Have received systemic or inhaled glucocorticoid therapy
• Women of childbearing potential
• Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

LY3532226

Experimental group

Treatment:

Drug: LY3532226

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo